BRIDGEWATER, N.J.--(BUSINESS WIRE)--The Board of Directors of Alpharma Inc. (NYSE: ALO), a global specialty pharmaceutical company, today urged shareholders to take no action with respect to the announcement by King Pharmaceuticals, Inc. (NYSE: KG) that it intends to commence a tender offer to acquire all of the outstanding shares of Alpharma for $37 per share until the Board has announced its position with respect to the offer. The Board will make a recommendation to Alpharma’s shareholders within 10 business days following the commencement of the tender offer.
